(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 May 2020 (14.05.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/094471 A1

(51) International Patent Classification:
A61K 47/54 (2017.01) *A61P 35/00* (2006.01)
A61K 47/65 (2017.01) *A61K 47/60* (2017.01)

(21) International Application Number:
PCT/EP2019/079601

(22) International Filing Date:
30 October 2019 (30.10.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18204423.0 05 November 2018 (05.11.2018) EP

(71) Applicant: **BAYER PHARMA AKTIENGESELLSCHAFT** (legal representative of the deceased inventor) [DE/DE]; Müllerstr. 178, 13353 Berlin (DE).

(72) Inventors: **LERCHEN, Hans-Georg**; Sürderstr. 3, 51375 Leverkusen (DE). **STELTE-LUDWIG, Beatrix**; Görtzheide 10f, 42489 Wülfrath (DE). **KOPITZ, Charlotte, Christine**; Ringstr. 33, 14612 Falkensee (DE).

(72) Inventor: **KELDENICH, Jörg** *(deceased)*.

(74) Agent: **BIP PATENTS**; Alfred-Nobel-Str. 10, 40789 Monheim am Rhein NRW (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2020/094471 A1

(54) Title: CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDS

(57) Abstract: The present invention relates to novel pharmaceutical compounds comprising of an $\alpha_v\beta_3$ integrin antagonist, a linking unit comprising of L-Val – L-Pro – L-Asp cleavable by elastase, a polyethyleneglycol (PEG) spacer and a cytotoxic element, to processes for preparation thereof, to the use thereof for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.